ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO472

Regular Monitoring for Nasal Carriage of Staphylococcus aureus May Reduce Risk of Peritoneal Dialysis Associated Infections

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Dukka, Hari, University of Derby and Burton, Derby, United Kingdom
  • Onwuchekwa, Ugonna, University of Derby and Burton, Derby, United Kingdom

Staphylococcus Aureus (SA) causes a significant proportion of Peritoneal dialysis (PD) associated infections. Patients with nasal carriage of SA are four times more likely to develop PD catheter exit site infections, which can lead to peritonitis. Mupirocin has been used to treat SA nasal carriage.


We did a retrospective study to see if patients receiving PD in our department were being monitored for SA carriage with nasal swabs, every 3 months as per department policy and the impact it had on PD associated infections (PDAI). The study period was 2.5 years and electronic data base was used to capture information. Timing of nasal swabs and any PDAI were captured.


60 patients were analysed during the study period. The mean age72+/-4 years. 23 patients received 3 monthly nasal swabs to identify SA carriage( group 1). The rest had swabs done at median time of 4 months (4-17 months) ( group 2). 29 patients during this study period developed PDAI. There were 26 peritonitis episodes and 23 exit site infections. The relative risk of developing PDAI with a positive nasal swab was 1.5 (odds ratio of 2.34). Patients in group 1 who had 3 monthly monitoring and appropriate treatment with mupirocin (n= 8) developed PDAI and in group 2 the incidence was (n= 21). Three monthly monitoring for nasal carriage of SA reduced risk of PDAI by 22%.


Patients on PD should have regular and timely monitoring for nasal SA carriage. This may reduce the incidence of PDAI.